Effect of Topical Olopatadine And Epinastine in The Botulinum Toxin B—Induced Mouse Model of Dry Eye

Abstract

Topical olopatadine and epinastine do not cause significantly additional damage to the compromised ocular surface secondary to dry eye after continuous 4-week, twice-daily application. Topical olopatadine and epinastine appear to have comparable effects on aqueous tear-production and corneal-surface changes in this mouse model.

Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China

“…The finding in Wisconsin [41] showed that dry eye could be related to the use of antihistamines that have anticholinergic properties owing to high muscarinic receptor binding. Systemic antihistamines, including old and newer generations, have been shown to potentially cause clinically meaningful damage to the ocular surface as a result of anti-muscarinic activity on the M3 receptors that results in a decrease in both aqueous and mucin tear [42]. There is no consensus of opinion about the effect of estrogen on DED.…”

In Vitro Assessment of the Cytotoxicity of Anti-allergic Eye Drops Using 5 Cultured Corneal and Conjunctival Cell Lines

“…Tranilast, which is the active ingredient in Tramelas PF, has an inhibitory effect on cell proliferation 12 . Clinical and experimental studies have indicated that olopatadine, which is in Patanol, results in mild ocular surface damage 13,14 .…”

Effect of short‐term diphenhydramine administration on aqueous tear production in normal dogs

“…To the authors’ knowledge, the effect of topical antihistamines on tear production in dogs has not been evaluated. In mice with botulinum toxin B‐induced dry eye, topical olopatadine and epinastine did not have a significant effect on aqueous tear production 29 . Another study evaluating mice showed olopatadine but not epinastine to cause a significant decrease in tear volume 30 .…”